Extensively StudiedHealing & Recovery

Abaloparatide

Tymlos

PTHrP Analog | Anabolic Bone-Building Agent

Half-life

~1.7 hours

Chain length

34 amino acids

Reference frequency

Once daily

Research overview

DoseGear research brief

Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.

Mechanism of action

Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic parathyroid-hormone-related-protein analog approved in the United States in 2017.

What it is researched for

Osteoporosis and fracture prevention through PTH1-receptor agonism and bone-formation signaling.

Research observation window

The cited ACTIVE/ACTIVExtend research included an 18-month abaloparatide phase; this is a study duration, not an onset estimate.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Osteoporosis treatment	80 mcg	Once daily	SubQ (periumbilical abdomen)

Reference cycle

Up to 2 years (lifetime maximum)

Reference storage

Refrigerate pre-filled pen at 2-8°C, do not freeze; Discard after 30 days even if medication remains

Safety context

Reported side effects

Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo

Contraindications & cautions

Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime

Scientific references

01
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial)
Scientific citationEffect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial). JAMA (2016).
02
ACTIVExtend Trial: Abaloparatide Followed by Alendronate
Scientific citationACTIVExtend Trial: Abaloparatide Followed by Alendronate. Mayo Clinic Proceedings (2017).
03
Phase 2 Dose-finding Study of BA058 in Postmenopausal Women
Scientific citationPhase 2 Dose-finding Study of BA058 in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism (2015).
04
Profile of Abaloparatide and Its Potential in Postmenopausal Osteoporosis
Scientific citationProfile of Abaloparatide and Its Potential in Postmenopausal Osteoporosis. Cureus (2017).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Healing & Recovery